OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

Clinical trial NCT07739017 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07739017
Sponsor: Olivia Newton-John Cancer Research Institute
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Glioblastoma Newly Diagnosed MGMT Unmethylated Glioblastoma

Start date: 2026-12-01
Primary completion: 2028-06-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.